PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
1-Year Est. Return
21.39%
1 Year Est. Return
+21.39%
AUM
$1.3B
AUM Growth
-$9.07M
(-0.69%)
Holding
89
Top Buys
| 1 | +$38.4M | |
| 2 | +$23.5M | |
| 3 | +$21.4M | |
| 4 |
CVS Health
CVS
|
+$21.2M |
| 5 |
Becton Dickinson
BDX
|
+$21M |
Top Sells
| 1 | +$25.6M | |
| 2 | +$22.8M | |
| 3 | +$21.7M | |
| 4 |
UnitedHealth
UNH
|
+$20.8M |
| 5 |
Eli Lilly
LLY
|
+$20.5M |
Sector Composition
| 1 | Healthcare | 97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Neurocrine Biosciences
NBIX
$14B
| – | – |
-166,803
|
|
||
77
Novo Nordisk
NVO
$237B
| – | – |
0
|
|
||
78
Invesco S&P 500 Equal Weight ETF
RSP
$74.7B
| – | – |
-108,041
|
|
||
79
SPDR S&P 500 ETF Trust
SPY
$663B
| – | – |
-12,427
|
|
||
80
Stryker
SYK
$148B
| – | – |
-32,349
|
|
||
81
Teva Pharmaceuticals
TEVA
$21.8B
| – | – |
-397,024
|
|
||
82
TG Therapeutics
TGTX
$5.49B
| – | – |
-98,674
|
|
||
83
United Therapeutics
UTHR
$19.1B
| – | – |
-52,500
|
|
||
84
Veeva Systems
VEEV
$47.5B
| – | – |
-55,383
|
|
||
85
SPDR S&P Biotech ETF
XBI
$6.21B
| – | – |
0
|
|
||
86
Health Care Select Sector SPDR Fund
XLV
$36B
| – | – |
-83,806
|
|
||
|
ITCI
87
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-40,610
|
|